Shots: Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for […]readmore
Tags : Roche
Shots: The data includes results from P-III extension studies of OPERA I, OPERA II and ORATORIO assessing Ocrevus in patients with RMS and PPMS earlier treated with IFN beta-1α or […]readmore
Shots: Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III), Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I) Additionally, presenting […]readmore
Shots: Hemlibra’s approval is based on results of P-III HAVEN 3 study assessing Hemlibra qw or q2w vs no prophylaxis and HAVEN 4 study assessing Hemlibra q4w, in patients aged […]readmore
Shots: Tusk to get an upfront $81.2M with contingent payments up to $678.9M (€ 585M) based on certain milestones Roche plans to continue the development of novel Ab developed by […]readmore
Shots: The data contains HAVEN 3 (N=152) study evaluating Hemlibra (emicizumab) prophylaxis vs no prophylaxis with patients aged ≥12 yrs HAVEN 3 results: (reduction in treated bleeds 96%/qw, 97%/q2w); (zero […]readmore
Shots: Alecensa approval in china is after 8 & 9 mos post EMA and US FDA approvals, Alecensa is now approved in over 57 countries The approval is based on […]readmore
Shots: The FDA’s BT designation is based on P-Ib (NCT02715531) study assessing Tecentriq (1200mg) + Avastin (15 mg/kg) in 23 patients with advanced or metastatic first-line HCC The P-Ib study […]readmore
Shots: The FDA’s BT designation is based on P-III HAVEN 3 study assessing Hemlibra vs no prophylaxis in 152 patients in ratio (2:2:1) with hemophilia A + prior treated with […]readmore